Relatlimab lead-in was characterized by clustering of CD8+ T and FOXP3+ T regulatory cells in the tumor microenvironment, enrichment in inhibitory receptor pathways and associated with worse PFS. The gene discussed is CD8A; the disease is neoplasm.